Schizophrenia Daily News Blog

Poor Results from Secretin Trial

Phase II clinical trials with secretin show that the treatment had no more effect than placebo, despite hopeful results from phase I studies.

Repligen, the biotechnology company that develops the treatment, reported that "moods and behavior of patients treated with the secretin during [phase II trial] was about the same as those who received a placebo."

Phase I trials, carried out at the University of North Carolina, had initially reported transient symptom improvements in patients who recieved secretin treatment vs. those that did not.

Source: "Repligen reports poor results for schizophrenia treatment", Feb 4 2005. The Boston Herald (http://www.bostonherald.com)